Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High Grade Squamous Intraepithelial Lesion Clear all
Terminated Not applicable Interventional

Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer

NCT02140021
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenocarcinoma In Situ, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Cervical Squamous Intraepithelial Neoplasia, Early Invasive Cervical Adenocarcinoma, Early Invasive Cervical Squamous Cell Carcinoma, High Grade Cervical Squamous Intraepithelial Neoplasia, High Grade Vaginal Intraepithelial Neoplasia, Low Grade Vaginal Intraepithelial Neoplasia, Stage I Cervical Cancer AJCC v8, Stage I Vaginal Cancer AJCC v8, Stage I Vulvar Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA Vaginal Cancer AJCC v8, Stage IA Vulvar Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB Vaginal Cancer AJCC v8, Stage IB Vulvar Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Vaginal Cancer AJCC v8, Stage II Vulvar Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Vaginal Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Vaginal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Adenocarcinoma, Vulvar Adenocarcinoma, Vulvar High Grade Squamous Intraepithelial Lesion, Vulvar Intraepithelial Neoplasia, Vulvar Squamous Cell Carcinoma, Vulvar Squamous Intraepithelial Lesion
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

NCT06075264
View directory record Official record
Conditions
Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions
Artesunate ointment, Placebo ointment
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effectiveness of High Resolution Microendoscopy for People Living With HIV

NCT04563754
View directory record Official record
Conditions
Anal High Grade Squamous Intraepithelial Lesion
Interventions
mHRME (Mobile High resolution microendoscope), Proflavine Hemisulfate, High resolution anoscopy
Diagnostic Test · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Phase 2 Interventional

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

NCT06577311
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Aminolevulinic acid hydrochloride 10% topical gel with Red Light
Combination Product
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

NCT03202992
View directory record Official record
Conditions
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasms
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
27 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

NCT00550589
View directory record Official record
Conditions
Anal Cancer, Precancerous Condition
Interventions
cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination
Drug · Genetic · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 1 Interventional Results available

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

NCT03197025
View directory record Official record
Conditions
Human Papillomavirus, HPV-16, High Grade Squamous Intraepithelial Lesion
Interventions
Aldesleukin, E6 T Cell Receptor (TCR)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Early Phase 1 Interventional Results available

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

NCT03196180
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2, High Grade Cervical Intraepithelial Neoplasia
Interventions
Imiquimod, Topical Fluorouracil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Not yet recruiting Phase 1 Interventional

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

NCT06233331
View directory record Official record
Conditions
Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
Interventions
Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment, Vulvar/ Perianal Biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Not listed Phase 2 Interventional

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

NCT06409195
View directory record Official record
Conditions
Non-Melanoma Skin Cancers
Interventions
SM-020 1% Gel
Drug
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jul 23, 2026, 11:41 PM EDT
Completed No phase listed Observational

Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions

NCT02418494
View directory record Official record
Conditions
High Grade Anal Canal Squamous Intraepithelial Neoplasia, HIV Infection
Interventions
Concept Elicitation, Comprehension Assessment
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
35 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

NCT03937791
View directory record Official record
Conditions
Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
Interventions
E7 T Cell Receptor (TCR)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

NCT03603808
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions
Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
Device · Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

NCT02576561
View directory record Official record
Conditions
Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions
Interventions
TVGV-1, GPI-0100, Placebo
Biological
Lead sponsor
THEVAX Genetics Vaccine
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Tucson, Arizona • Lakewood, Colorado • Port Orange, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

NCT02481414
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
PepCan, Candin®
Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety of Anal Curcumin

NCT06626230
View directory record Official record
Conditions
Anal High Grade Squamous Intraepithelial Lesion
Interventions
Curcuminoid Capsules
Drug
Lead sponsor
Lisa Flowers
Other
Eligibility
30 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Phase 2 Interventional

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

NCT06206564
View directory record Official record
Conditions
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
Interventions
Artesunate ointment, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Not yet recruiting Phase 2 Interventional

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

NCT06949800
View directory record Official record
Conditions
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions
EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jul 23, 2026, 11:41 PM EDT
Not listed Phase 2Phase 3 Interventional

Topical Imiquimod for Bowen's Disease of the Head and Neck

NCT00384124
View directory record Official record
Conditions
Bowens Disease
Interventions
Imiquimod
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2008 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

NCT03333694
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)
Interventions
Cutaneous Cream application, Placebo Cutaneous Cream application
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Phoenix, Arizona • Fountain Valley, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

NCT04712851
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Interventions
Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

NCT05381597
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ
Interventions
Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream

NCT00622440
View directory record Official record
Conditions
Anus Neoplasms
Interventions
AIJP (Arnebia Indigo Jade Pearl), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 99 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 23, 2026, 11:41 PM EDT